Last reviewed · How we verify
ET0038
At a glance
| Generic name | ET0038 |
|---|---|
| Sponsor | Etern BioPharma (Shanghai) Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors (PHASE1)
- SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ET0038 CI brief — competitive landscape report
- ET0038 updates RSS · CI watch RSS
- Etern BioPharma (Shanghai) Co., Ltd portfolio CI